Clinical Trials

Text Size A A

E-Mail to a Friend

secret  Click to Play Audio

SCCA Clinical Studies: Phase 1 Program

Phase I studies are critical to future patients and the health-care industry. Potentially speeding the development of new therapies, phase I studies require a high level of unique technical and scientific competencies, like those found at SCCA’s Phase I Cancer Clinical Trials Program.

Located in the Clinical Trials Unit (CTU) at SCCA, our program’s researchers have access to leading research facilities at Fred Hutchinson Cancer Research Center, the source of multiple medical breakthroughs and home to Nobel Prize winning researchers, and University of Washington Medicine where advanced technologies such as positron emission tomography (PET) and other essential tools support thorough research studies.

We're currently enrolling patients into the following trials:

All solid tumor malignancies

Breast Cancer

  • SGN-LIV1A for Breast Cancer
    A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer
  • PF-06664178 for Advanced Solid Tumors
    A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors

GI Cancer

 GU Cancer

Gynecologic Cancer

Head & Neck Cancers

Hematologic Malignancies

Lung Cancer


Renal Cell Carcinoma

  • A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)